Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease involving multiple liver cell types that affects nearly one third of people worldwide. NAFLD can progress to more severe forms of liver disease such as non-alcoholic steatohepatitis (NASH) and fibrosis. However, there are currently no approved biomarkers or therapies. We are looking for a highly-motivated individual to drive cutting-edge research in modelling inflammation-driven health-to-disease in the NAFLD-to-NASH transition phase. You will be involved in human liver disease modelling including development of a unique, dynamic human liver acinus-on-a-chip system to unravel relevant molecular pathways, targets and biomarkers. Expertise and interest in tissue engineering (2D-3D organotypic models) and applying novel analytical approaches is highly desirable.